» Articles » PMID: 28058165

Evaluation of Follow-Up and Treatment Results in Coats' Disease

Overview
Specialty Ophthalmology
Date 2017 Jan 7
PMID 28058165
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The aim of this study was to evaluate the clinical features, follow-up and treatment results of patients diagnosed with Coats' disease.

Materials And Methods: Medical records of 27 patients diagnosed with Coats' disease in our clinic were reviewed retrospectively. All patients underwent complete ophthalmological examination and fundus photography was taken. Disease stage and treatment methods used were recorded.

Results: Twenty-seven eyes of 27 patients were included in the study. Mean age was 9.03 years; 21 patients were male and 6 were female. Three patients were older than 18 years old. Based on the Shields classification, 1 (3.7%) eye was stage 2A, 4 (14.8%) eyes were stage 2B, 6 (22.2%) were stage 3A1, 3 (11.1%) were stage 3A2, 1 (3.7%) was stage 3B, 4 (14.8%) were stage 4 and 8 (29.6%) were stage 5. Fourteen patients underwent treatment, 12 of whom had combined therapy. The most common treatment modalities were laser photocoagulation and cryotherapy. Encircling band was done in one patient and pars plana vitrectomy in 3 patients. Enucleation was done in 5 patients.

Conclusion: Coats' disease is a chronic disease and main goal of treatment is to eliminate the vascular anomalies and their complications using repetitive combination therapies. Treatment in the early stages can lead to functional success, and in advanced stages can result in a salvageable eye.

Citing Articles

Metabolomic comparison followed by cross-validation of enzyme-linked immunosorbent assay to reveal potential biomarkers of diabetic retinopathy in Chinese with type 2 diabetes.

Wang Z, Tang J, Jin E, Ren C, Li S, Zhang L Front Endocrinol (Lausanne). 2022; 13:986303.

PMID: 36157454 PMC: 9492931. DOI: 10.3389/fendo.2022.986303.


Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center.

Shields C, Udyaver S, Dalvin L, Lim L, Atalay H, Khoo C Indian J Ophthalmol. 2019; 67(6):772-783.

PMID: 31124485 PMC: 6552575. DOI: 10.4103/ijo.IJO_449_19.

References
1.
Smithen L, Brown G, Brucker A, Yannuzzi L, Klais C, Spaide R . Coats' disease diagnosed in adulthood. Ophthalmology. 2005; 112(6):1072-8. DOI: 10.1016/j.ophtha.2004.12.038. View

2.
Grosso A, Pellegrini M, Cereda M, Panico C, Staurenghi G, Sigler E . Pearls and pitfalls in diagnosis and management of coats disease. Retina. 2015; 35(4):614-23. DOI: 10.1097/IAE.0000000000000485. View

3.
Gaillard M, Mataftsi A, Balmer A, Houghton S, Munier F . ranibizumab in the management of advanced Coats disease Stages 3B and 4: long-term outcomes. Retina. 2014; 34(11):2275-81. DOI: 10.1097/IAE.0000000000000248. View

4.
Zhao Q, Peng X, Chen F, Zhang Y, Wang L, You Q . Vascular endothelial growth factor in Coats' disease. Acta Ophthalmol. 2013; 92(3):e225-8. DOI: 10.1111/aos.12158. View

5.
Othman I, Moussa M, Bouhaimed M . Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications. Br J Ophthalmol. 2009; 94(5):606-10. DOI: 10.1136/bjo.2009.168013. View